Circular RNA (circRNA) had been confirmed to participate in ulcerative colitis (UC) development. Circular RNA_0001187 (Circ_0001187) had been found to be overexpressed in patients with Crohn disease. Therefore, circ_0001187 might be an important circRNA regulating intestinal inflammatory diseases. However, the role and mechanism of circ_0001187 in UC progression remains unclear. The colonic mucosal tissues were obtained from 23 UC patients and 23 healthy normal controls. Tumor necrosis factor-α (TNF-α) was used to mimic UC cell model in vitro . Cell function was assessed by cell counting kit 8 assay, EdU assay, flow cytometry, ELISA assay and oxidative stress detection. RNA interaction was confirmed by dual-luciferase reporter assay and RIP assay. Serum exosomes were isolated by ultracentrifugation and identified by transmission electron microscope. Circ_0001187 was overexpressed in UC patients. Circ_0001187 knockdown enhanced the proliferation, while suppressed apoptosis, inflammation and oxidative stress of TNF-α-induced FHC cells. Circ_0001187 acted as miR-1236-3p sponge, and the effects of circ_0001187 downregulation on TNF-α-induced FHC cell injury were overturned by miR-1236-3p inhibitor. MYD88 was targeted by miR-1236-3p, and circ_0001187 sponged miR-1236-3p to regulate MYD88. MYD88 knockdown alleviated TNF-α-induced FHC cell injury, and its upregulation revoked the inhibition effect of miR-1236-3p on TNF-α-induced FHC cell injury. High expression of circ_0001187 also was observed in the serum exosomes of UC patients. Our data confirmed that circ_0001187 facilitated UC progression through miR-1236-3p/MYD88 axis, which might be a potential treatment and diagnosis biomarker for UC.

Cisplatin (DDP) is a widely used chemotherapeutic agent that plays an unsubstitutable role in treating various tumors. However, it is crucial to identify solutions and alternatives for DDP-mediated renal injury. This acute kidney injury (AKI) is characterized by the occurrence of ferroptosis, which is defined as an iron-catalyzed regulatory necrosis mediated by excessive lipid peroxidation. To solve this problem, we concentrate on the potential function of nanoparticles to devise a new technique to prevent DDP-induced kidney injury. Selenium nanoparticles (Se NPs) containing the trace element, selenium, have been shown to exhibit strong oxidation resistance. However, the ability of Se NPs to treat DDP-induced kidney injury remains largely unexplored. Here, we elaborate the role of our self-developed Se/Albumin nanoparticles (Se/Albumin NPs, SA NPs) in alleviating DDP-induced acute kidney damage using a murine model. Mice with acute kidney injury (AKI) had significantly impaired renal function and reduced body weight. Hematoxylin–eosin staining (H&E) and periodic acid-Schiff (PAS) staining, which was carried out to determine the extent of the morphological changes in renal tubules, revealed severe interstitial edema. Further studies revealed an increase in malonaldehyde (MDA), a decrease in superoxide dismutase (SOD), and reduced glutathione (GSH) and glutathione peroxidase (GPx) levels in the renal tubule tissues and cells under an electron microscope, thereby indicating pro-apoptotic changes. Moreover, the levels of ferroptosis-related proteins glutathione peroxidase 4 (GPX4) andferroportin1 (FPN1) decreased while those of transferrin and ACSL4 increased. Our study reveals that SA NPs are more potent at ameliorating these damages than Se NPs. In all, the results suggest that the SA NPs reduce DDP-induced AKI by inhibiting ferroptosis, indicating the potential therapeutic role of SA NPs in acute renal damage.

ObjectiveThis study evaluated the role of neoadjuvant chemotherapy (NACT) with bevacizumab intraperitoneal perfusion in advanced ovarian cancer (AOC).MethodsIn this study, 80 patients with advanced epithelial ovarian cancer (stage IIIc or IV) who received NACT at the Central Hospital of Zhuzhou between February 2019 and October 2020 were enrolled. Patients were randomized to receive paclitaxel plus carboplatin (TC) or TC plus intraperitoneal perfusion of bevacizumab (TCB). The effect of chemotherapy was assessed following two cycles of chemotherapy. Cancer antigen 125 (CA125), tumor size, ascites volume, bleeding volume, duration of operation, surgical satisfaction rate, complication rate, and residual tumor were assessed to monitor response to chemotherapy.ResultsTreatment with TCB regimen significantly reduced serum levels of CA125 and ascites volume (p < 0.001). Meanwhile, the TCB group had significantly lower intraoperative blood loss and shorter operation time (p < 0.001). Most importantly, patients treated with TCB regimen had a higher surgical satisfaction rate (p < 0.01). Moreover, the incidence of postoperative wound infection, hypoproteinemia, abdominal distension, and fever was lower in the TCB group compared with the TC group. Assessment of adverse reactions during chemotherapy showed no severe complications between the two groups.ConclusionsThe results demonstrated that the TCB regimen is superior to the TC regimen alone in the treatment of AOC. These findings could help improve the surgical satisfaction rate, provide more effective treatment strategies to prolong progression-free survival and reduce postoperative complications, and promote surgical recovery in AOC.